Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03682289 · ClinicalTrials.gov registry record · Phase 2
Ceralasertib (AZD6738) Alone and in Combination With Olaparib or Durvalumab in Patients With Solid Tumors
A Phase 2 study of Metastatic Malignant Solid Neoplasm and Clear Cell Renal Cell Carcinoma, sponsored by Rahul Aggarwal.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 89
- Enrollment target
- 3
- Study locations
NCT03682289: Recruiting Phase 2 study of Metastatic Malignant Solid Neoplasm and Clear Cell Renal Cell Carcinoma, sponsored by Rahul Aggarwal.
NCT03682289 is a Phase 2 study of Metastatic Malignant Solid Neoplasm and Clear Cell Renal Cell Carcinoma that is actively recruiting participants, run by Rahul Aggarwal. The registered enrollment target is 89 participants, below the 205-participant average among 92 other Metastatic Malignant Solid Neoplasm trials with a reported enrollment target (57% lower). The trial reports 3 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03682289, a Phase 2 study of Metastatic Malignant Solid Neoplasm and Clear Cell Renal Cell Carcinoma, is actively recruiting participants, sponsored by Rahul Aggarwal.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 89 participants
- Enrollment target
- 3
- Study locations
Study Summary
This phase II trial studies how well ceralasertib, am Ataxia telangiectasia and Rad3-related (ATR) kinase inhibitor, works alone or in combination with olaparib or durvalumab in treating participants with renal cell carcinoma (RCC), urothelial carcinoma, all pancreatic cancers, endometrial cancer, and other solid tumors excluding clear cell ovarian cancer that have spread to nearby tissue or lymph nodes or other parts of the body. ATR kinase inhibitor AZD6738 and olaparib or durvalumab may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. It is not known if giving ATR kinase inhibitor AZD6738 with or without olaparib or durvalumab may work better in treating participants with solid tumors.
Primary Outcome
On overall response will be reported as a percentage of participants with a complete response (CR) or partial response (PR) as measured by the Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1
Conditions Studied
Interventions
- DRUG Olaparib
- DRUG Durvalumab
- DRUG Ceralasertib
Study Locations (3)
California
- City of Hope Comprehensive Cancer Center - Duarte
- University of California, San Francisco - San Francisco
Illinois
- University of Chicago Comprehensive Cancer Center - Chicago
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 89 participants |
| Start Date | 2019-01-17 |
| Est. Completion | 2028-03-31 |
| Phase | Phase 2 |
What NCT03682289 shows while recruiting
NCT03682289 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 89 participants, a relatively small participant target, below the 205-participant average among 92 other Metastatic Malignant Solid Neoplasm trials with a reported enrollment target (57% lower).
The record links to 10 conditions, with Metastatic Malignant Solid Neoplasm appearing as the primary indexed condition, and to 3 interventions - of which Olaparib is the first listed.
NCT03682289 reports a single indexed study location in California, Illinois.
Frequently Asked Questions
What is clinical trial NCT03682289 about?
NCT03682289 is a clinical study titled "Ceralasertib (AZD6738) Alone and in Combination With Olaparib or Durvalumab in Patients With Solid Tumors". This phase II trial studies how well ceralasertib, am Ataxia telangiectasia and Rad3-related (ATR) kinase inhibitor, works alone or in combination with olaparib or durvalumab in treating participants with renal cell carcinoma (RCC), urothelial carcinoma, all pancreatic cancers, endometrial cancer, a...
What is the current status of trial NCT03682289?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 89 participants. The study started on 2019-01-17. Estimated completion is 2028-03-31.
What conditions does trial NCT03682289 study?
This clinical trial studies the following conditions: Metastatic Malignant Solid Neoplasm, Clear Cell Renal Cell Carcinoma, Metastatic Renal Cell Carcinoma, Metastatic Pancreatic Cancer, Metastatic Urothelial Carcinoma.
What interventions are being tested in trial NCT03682289?
The interventions under investigation include: Olaparib (DRUG), Durvalumab (DRUG), Ceralasertib (DRUG).
Who is sponsoring clinical trial NCT03682289?
This trial is sponsored by Rahul Aggarwal, which has 13 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03682289 being conducted?
This trial has 3 study locations across California, Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Metastatic Malignant Solid Neoplasm
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT03682289's enrollment target sits among peer trials
89 32nd of 92 higher than 61 of 92 other Metastatic Malignant Solid Neoplasm trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Metastatic Malignant Solid Neoplasm trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Testing the Use of AMG 510 (Sotorasib) and Panitumumab as a Targeted Treatment for KRAS G12C Mutant Solid Tumor Cancers (A ComboMATCH Treatment Trial)
RECRUITING · Phase 2
-
Durvalumab in Combination With Chemotherapy in Treating Patients With Advanced Solid Tumors, DURVA+ Trial
RECRUITING · Phase 2
-
Pemetrexed Response in Relation to Tumor Alterations of Gene Status for the Treatment of Patients With Metastatic Urothelial Bladder Cancer and Other Solid Tumors
RECRUITING · Phase 2
-
Testing the Combination of the Anti-cancer Drugs ZEN003694 (ZEN-3694) and Talazoparib in Patients With Advanced Solid Tumors, The ComBET Trial
RECRUITING · Phase 2
-
Larotrectinib for the Treatment of NTRK Amplification Positive, Locally Advanced or Metastatic Solid Tumors
RECRUITING · Phase 2
-
Personalized Antibody-Drug Conjugate Therapy Based on RNA and Protein Testing for the Treatment of Advanced or Metastatic Solid Tumors (The ADC MATCH Screening and Treatment Trial)
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04787939 · 89 participants · NA
Early Feeding After Oral Cavity Reconstruction
- NCT05480449 · 89 participants · Phase 1
Autologous HuCART19 T Cells Manufactured Using the CliniMACS Prodigy Platform for Pediatric B-ALL (huCART19 Prodigy)
- NCT05604131 · 89 participants · Phase 2
Cardiac MRI-guided Deferiprone Therapy for Acute Myocardial Infarction Patients
- NCT07015983 · 89 participants · Phase 2
A Study of CC-97540 (BMS-986353 or Zola-cel), CD19-Targeted NEX-T CAR T Cells, in Participants With Active SLE Despite Immunosuppressants (Breakfree-SLE)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI